Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.
Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.
Int Immunopharmacol. 2021 Oct;99:107968. doi: 10.1016/j.intimp.2021.107968. Epub 2021 Jul 10.
The current COVID-19 pandemic has become a global public health crisis and presents a serious challenge in treatment of severe COVID pneumonia patients. With an imperative need for an effective treatment, we aimed to study the effectiveness of Pentaglobin, an intravenous immunoglobin in the treatment of severe Covid-19 pneumonia patients.
This is an open-label non-randomised controlled study. Patients in the study group (n = 17) received Pentaglobin in addition to standard therapy and the control group (n = 19) received only the standard of care treatment. Severity of illness were quantified by severity scores and inflammatory laboratory parameters were compared between the two groups.
The average length of hospital stay in pentaglobin group were 12.35 ± 6.98 days compared to 10.94 ± 4.62 days in standard treatment group with mean difference of 1.4 days (p value = 0.4). Pentaglobin did not provide an added advantage in terms of reducing the duration of hospital stay. There was no significant difference between both the groups in terms of requirement of invasive ventilation (p = 0.56) and mortality (p = 0.86). CT Severity score (OR = 1.39 95% CI = 1.09-1.77, P = 0.01), APACHE II score (OR = 1.16 95% CI = 0.99-1.35, P = 0.05) and the SOFA score (OR = 2.11 95% CI = 1.13-3.93, P = 0.02) were independent predictors of mortality.
The administration of pentaglobin in COVID -19 patients has no significant effect in reducing the risk of mechanical ventilation or death, in disease worsening or in reduction of inflammation.
当前的 COVID-19 大流行已成为全球公共卫生危机，给重症 COVID 肺炎患者的治疗带来了严峻挑战。鉴于对有效治疗方法的迫切需求，我们旨在研究静脉注射免疫球蛋白 Pentaglobin 在治疗重症 COVID-19 肺炎患者中的疗效。
这是一项开放标签、非随机对照研究。研究组（n=17）患者在标准治疗的基础上加用 Pentaglobin，对照组（n=19）患者仅接受标准治疗。通过严重程度评分量化疾病严重程度，并比较两组之间的炎症实验室参数。
Pentaglobin 组的平均住院时间为 12.35±6.98 天，标准治疗组为 10.94±4.62 天，平均差异为 1.4 天（p 值=0.4）。Pentaglobin 并不能在缩短住院时间方面提供额外的益处。两组在需要有创通气（p=0.56）和死亡率（p=0.86）方面无显著差异。CT 严重程度评分（OR=1.39，95%CI=1.09-1.77，P=0.01）、APACHE II 评分（OR=1.16，95%CI=0.99-1.35，P=0.05）和 SOFA 评分（OR=2.11，95%CI=1.13-3.93，P=0.02）是死亡的独立预测因素。
在 COVID-19 患者中使用 Pentaglobin 并没有显著降低机械通气或死亡、疾病恶化或炎症减少的风险。
